{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061525","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.410773+00:00","generated_at":"2026-06-08T07:17:23.630753+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TScan Therapeutics reports Q3 2023 net loss of $23.0M; cash runway into 2026","bullets":["Net loss $23.0M in Q3 2023 vs $16.2M in Q3 2022; revenue $3.9M (up from $3.4M) from collaboration.","Cash, equivalents, and marketable securities $215.4M as of Sept 30; funding operations into 2026.","FDA cleared IND for TSC-203-A0201 targeting PRAME; plans to file two additional INDs by year-end.","Expects initial heme program data at ASH Dec 2023; solid tumor Phase 1 enrollment by year-end 2023.","R&D expenses $22.7M, up $7.7M YoY due to clinical start-up costs and personnel expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061525","json":"https://secwatch.observer/filing/0000950170-23-061525.json","markdown":"https://secwatch.observer/filing/0000950170-23-061525.md","text":"https://secwatch.observer/filing/0000950170-23-061525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023061525/0000950170-23-061525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017023061525/tcrx-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:17:23.630753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}